If you're looking for blue chips to buy in September, then you may want to look at the ones listed below.
Here's why the team at Morgans are positive on these ASX 200 shares:
CSL Limited (ASX: CSL)
The first ASX 200 share to look at is CSL. It is one of the world's leading biotechnology companies, manufacturing and developing a portfolio of leading therapies and vaccines. This includes flu vaccines, immunoglobulins, and countless other plasma-based products. And while COVID-19 is weighing on plasma collections and is expected to lead to a decline in earnings in FY 2022, its long term future looks very positive.
Morgans remains positive on the company despite these headwinds. It currently has an add rating and $324.40 price target on its shares.
ResMed Inc. (ASX: RMD)
Another ASX 200 share to look at is ResMed. It is one of the world's leading sleep treatment-focused medical device companies. Over the last decade, ResMed has been growing its revenue and earnings at a very strong rate. This has been underpinned by its industry-leading products, growing software business, the increasing awareness of sleep disorders, and its investment in R&D.
Morgans appears confident this positive form will continue over the medium term. It currently has an add rating and $41.34 price target on ResMed's shares.
Telstra Corporation Ltd (ASX: TLS)
A final ASX 200 share to look at is Telstra. It could be a blue chip to buy thanks to its attractive valuation and the positive progress it is making with its T22 strategy. This strategy is creating a much leaner business and one which is expected to return to growth in the not so distant future. In fact, the company's CEO, Andy Penn, is targeting mid to high single digit operating earnings growth in FY 2022. He is then targeting further growth in FY 2023.
Morgans currently has an add rating and $4.34 price target on the company's shares. It also expects 16 cents per share fully franked dividends in FY 2022 and FY 2023.
